查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771558

Zilvisc 市場規模、佔有率和趨勢分析報告：按適應症、分銷管道、地區和細分市場預測，2025-2030 年

Zilbrysq Market Size, Share & Trends Analysis Report By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Zilvisc（Zilcoplan）市場成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球 Zilvisc（Zilcoplan）市場規模預計到 2030 年將達到 6.7958 億美元，預測期內的複合年成長率為 28.39%。

UCB 的First-in-Class自主給藥皮下補體 C5 抑制劑 Zilbrysq 正在迅速重新定義全身型重症肌無力 (gMG) 的治療模式。該藥物已在美國、歐盟、日本、加拿大和韓國核准，其獨特的給藥模式和標靶作用機制使其成為罕見自體免疫神經肌肉疾病領域的寶貴療法。

一個重要的促進因素是基於機制的標靶治療日益受到重視，尤其是對於皮質類固醇、靜脈注射免疫球蛋白 (IVIg) 或血漿置換治療效果不佳的鉅細胞性重症肌無力 (MG) 患者。 Zilvisc 能夠選擇性抑制終末補體激活，為臨床醫生提供精準干預，符合強調免疫特異性和長期安全性的現代治療流程。此外，其每日一次的皮下給藥配方打破了傳統的醫院依賴模式，實現了護理的分散化，並支持門診和家庭環境中的長期疾病控制。這不僅提高了患者的依從性，還降低了輸液相關成本，這對支付方來說是一個日益重要的考慮因素。 SC C5 缺乏直接競爭對手，進一步鞏固了其商業性定位。此外，罕見疾病政策框架，例如對罕見疾病的優先治療、加速核准以及主要市場的報銷優先，正在加速藥物的可及性和處方醫生的接受度。這些動態，加上可預測的治療人群和較低的治療重疊，繼續增強 Zilvisc 在 MG 治療領域的策略價值。

Zilcoplan 選擇性抑制補體成分 5 (C5) 的裂解，從而抑制膜攻擊複合物 (C5b-9) 的形成，該複合物在乙醯膽鹼受體 (AChR) 抗體陽性的巨噬細胞肌球蛋白 (gMG) 的神經肌肉接頭功能障礙中起著核心作用。與傳統的免疫抑制劑和生物製藥的靜脈注射不同，Zilvisc 以每日一次皮下注射的方式給藥，使患者能夠在家中自行給藥。這顯著減輕了治療負擔，並提高了長期依從性，尤其適用於從住院輸液治療過渡的患者。

截至2024年，Zirbisc已佔據gMG適應症的100%佔有率，由於PNH、ALS和IMNM的臨床計畫已策略性終止，因此並未積極開發其他適應症。然而，其強大的療效、便捷的皮下給藥以及直至2030年的孤兒藥專營權，使其擁有巨大的商業性護城河，並在核准人群中擁有永續收益的潛力。

到2024年，專科藥局的配藥量將佔到70%以上，這反映了對病患教育、遵從性監測和低溫運輸物流的需求。醫院藥房將繼續在啟動和支持新診斷病例和複雜病例的治療方面發揮作用。同時，家庭醫療保健提供者是成長最快的分銷領域，這得益於對分散式照護和改善家庭治療基礎設施的需求不斷成長。

2023年10月，美國FDA核准了Zilvisc，該批准基於關鍵的RAISE研究，該研究表明，與安慰劑相比，Zilvisc在MG-ADL和QMG評分方面具有統計學顯著改善。隨後，該藥物於2023年12月獲得歐盟委員會核准，並在英國（2024年1月）、加拿大（2024年7月）和韓國（2024年11月）獲得批准。此外，2024年5月檢驗的一項為期60週的擴展研究（RAISE-XT）核准了該藥物在治療遺傳性肌強直（gMG）方面的長期安全性和持續臨床效用。

此外，2024年11月宣布的一項人體因素檢驗研究證實，Zilvisc預填充式注射器易於患者、看護者和醫護人員使用，進一步增強了其居家適用性，並符合以患者為中心的護理模式。隨著全球精準醫療需求的成長，UCB正投資拓展亞太、拉丁美洲和中東地區的市場。公司策略重點在於供應鏈擴充性、真實世界臨床數據產生和數位化依從性平台，預計將增強全球擴張和醫療服務的連續性。

Zilvisc 的商業性成功反映了整個行業正轉向自主給藥、針對特異性機制的生技藥品，這些生物製劑無需住院即可提供持久的疾病控制。憑藉強大的臨床基礎和 SC補體抑制劑領域有限的直接競爭，Zilcoplan 預計將推動患者預後和生活品質的顯著改善，並繼續成為重組疾病領域的市場領導。

Zilvisc（Zilcoplan）市場報告重點

  • 整體重症肌無力 (gMG) 將在 2024 年繼續佔據市場主導地位，佔 100% 的市場佔有率。抗乙醯膽鹼受體 (AChR) 抗體陽性患者的高盛行率，加上 Zilcoplan 作為補體 C5 抑制劑的標靶作用機制，推動了該藥物的強勁應用。良好的臨床試驗結果、孤兒藥專營權以及被納入主要市場的最新治療指南，加速了該藥物的採用，尤其是在從傳統免疫抑制劑和輸液療法過渡的患者中。
  • 按銷售管道管道分類，專科藥房佔最大市場佔有率，2024 年佔 70.35%。這種優勢歸因於該藥物屬於高成本、稀有生物製藥，需要低溫運輸物流、病患教育和長期依從性支持。專科藥房在管理續藥核對和福利驗證方面也發揮關鍵作用，尤其是對於像 Zilcoplan 這樣的自行給藥療法。
  • 預計到2024年，北美將以77.78%的市場佔有率引領Zirvisc市場，這得益於該藥物的早期核准、處方醫生對補體抑製劑的廣泛接受以及遺傳性肌強直性肌炎（gMG）的高診斷率。該地區成熟的專科藥房網路以及支付方對高價孤兒藥的強烈報銷意願，進一步支撐了其強勁的商業表現。來自美國和加拿大臨床的真實世界證據預計將增強治療的連續性並擴大處方醫生群體。
  • UCB 繼續引領全球市場，這得益於策略性法規申報、有針對性的醫生教育以及對上市後資料產生的投資。該公司的長期成長策略以供應鏈擴充性、現實世界依從性支援和地理擴張為重點，尤其是在日本、加拿大和韓國等市場。 UCB 在補體介導的神經肌肉疾病領域的專業定位使其在補體替代療法有限的市場中擁有競爭優勢。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章 Zilvisc（Zilcoplan）市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
  • 管道分析
  • 專利到期分析
  • 定價分析

第4章 Zilvisc（Zilcoplan）市場：適應症業務分析

  • 2024年及2030年指示市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 全身性重症肌無力（gMG）
  • 其他

第5章 Zilvisc（Zilcoplan）市場：通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 專業藥房
  • 醫院/機構藥房
  • 家庭醫療保健提供者

第6章 Zilvisc（Zilcoplan）市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • UCB

第 8 章 結論

Product Code: GVR-4-68040-616-0

Zilbrysq (Zilucoplan) Market Growth & Trends:

The global zilbrysq (zilucoplan) market size is anticipated to reach USD 679.58 million by 2030 and is expected to expand at a CAGR of 28.39% during the forecast period, according to a new report by Grand View Research, Inc. Zilbrysq, a first-in-class self-administered subcutaneous complement C5 inhibitor developed by UCB, is rapidly redefining the treatment paradigm for generalized myasthenia gravis (gMG). Approved in the U.S., EU, Japan, Canada, and South Korea, the therapy's unique delivery model and targeted mechanism have positioned it as a high-value therapeutic in the rare autoimmune neuromuscular segment.

A key driver is the growing prioritization of targeted, mechanism-based therapies in generalized myasthenia gravis (gMG), particularly for patients inadequately managed by corticosteroids, IVIg, or plasma exchange. Zilbrysq's ability to selectively inhibit terminal complement activation provides clinicians with a high-precision intervention that aligns with modern treatment algorithms focused on immunological specificity and long-term safety. In addition, its once-daily subcutaneous formulation disrupts the traditional hospital-dependent model, enabling therapy decentralization and supporting long-term disease control in outpatient and home settings. This has not only improved patient adherence but also reduced infusion-related costs-an increasingly important consideration for payers. The absence of direct SC C5 competitors further enhances its commercial positioning. Moreover, rare disease policy frameworks, including orphan drug incentives, expedited approvals, and national reimbursement prioritization in key markets, have accelerated both access and prescriber uptake. These dynamics, combined with a predictable treatment population and low therapeutic redundancy, continue to reinforce Zilbrysq's strategic value within the gMG treatment landscape.

Zilucoplan works by selectively inhibiting the cleavage of complement component 5 (C5), preventing formation of the membrane attack complex (C5b-9), which plays a central role in neuromuscular junction damage in AChR antibody-positive gMG. Unlike traditional immunosuppressants or IV biologics, Zilbrysq is administered via once-daily subcutaneous injection, allowing patients to self-manage their therapy at home. This significantly reduces treatment burden and improves long-term adherence, particularly among patients transitioning away from hospital-based IV infusions.

As of 2024, Zilbrysq holds 100% indication share for gMG, with no active development in additional indications following the strategic discontinuation of clinical programs in PNH, ALS, and IMNM. However, its strong efficacy profile, convenient SC delivery, and orphan drug exclusivity until 2030 provide a significant commercial moat and sustained revenue potential in its approved population.

Specialty pharmacies serve as the primary distribution channel, accounting for over 70% of dispensed volumes in 2024, reflecting the need for coordinated patient education, adherence monitoring, and cold-chain logistics. Hospital pharmacies continue to play a role in treatment initiation and support for newly diagnosed or complex cases. Meanwhile, home healthcare providers represent the fastest-growing distribution segment, driven by increasing demand for decentralized care and improved at-home treatment infrastructure.

In October 2023, the U.S. FDA approved Zilbrysq, supported by the pivotal RAISE study, which demonstrated statistically significant improvements in MG-ADL and QMG scores versus placebo. Subsequently, the European Commission approved the therapy in December 2023, followed by authorizations in the UK (January 2024), Canada (July 2024), and South Korea (November 2024). Moreover, a 60-week extension study (RAISE-XT) published in May 2024 validated the drug's long-term safety and durability of clinical benefit in gMG.

Further bolstering its real-world readiness, a human factors validation study published in November 2024 confirmed the usability of Zilbrysq's prefilled syringe for patients, caregivers, and healthcare professionals, reinforcing its at-home applicability and alignment with patient-centric care models. As demand for precision therapies rises globally, UCB invests in market expansion across Asia Pacific, Latin America, and the Middle East. Strategic emphasis on supply chain scalability, real-world data generation, and digital adherence platforms is expected to enhance global reach and continuity of care.

The commercial success of Zilbrysq reflects a broader industry shift toward self-administered, mechanism-specific biologics that offer durable disease control without the need for hospital-based delivery. With a strong clinical foundation and limited direct competition in the SC complement inhibitor class, Zilucoplan is poised to remain a market leader in gMG, driving meaningful improvements in patient outcomes and quality of life.

Zilbrysq (Zilucoplan) Market Report Highlights:

  • Generalized Myasthenia Gravis (gMG) remained the exclusive and leading indication in the market in 2024, accounting for 100% of the market share. The high prevalence of anti-acetylcholine receptor (AChR) antibody-positive patients, combined with Zilucoplan's targeted mechanism of action as a complement C5 inhibitor, has driven strong adoption. Favorable clinical trial outcomes, orphan drug exclusivity, and inclusion in updated treatment guidelines across key markets have accelerated uptake, particularly among patients transitioning from conventional immunosuppressants or IV therapies.
  • Specialty Pharmacies held the largest share of the distribution channel segment in the market in 2024, accounting for 70.35% of dispensed volumes. This dominance is attributed to the drug's classification as a high-cost orphan biologic requiring cold-chain logistics, patient education, and long-term adherence support-all core competencies of specialty pharmacy providers. Specialty pharmacies also play a crucial role in managing refill coordination and benefit verification, especially for self-administered therapies like Zilucoplan.
  • North America led the Zilbrysq market in 2024 with a share of 77.78%, supported by early regulatory approval, broad prescriber familiarity with complement inhibitors, and high diagnostic rates for gMG. The region's well-established specialty pharmacy networks and payer willingness to reimburse high-cost orphan drugs further support strong commercial performance. Real-world evidence from U.S. and Canadian clinical practice is expected to reinforce treatment persistence and expand the prescriber base.
  • UCB continues to lead the global market, backed by strategic regulatory filings, targeted physician education, and investments in post-marketing data generation. The company's long-term growth strategy underpins its emphasis on supply chain scalability, real-world adherence support, and regional expansion, especially in markets like Japan, Canada, and South Korea. UCB's focused positioning within complement-mediated neuromuscular disorders strengthens its competitive advantage in a market with limited direct SC-based alternatives.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Zilbrysq (Zilucoplan) Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis
  • 3.5. Patent Expiry Analysis
  • 3.6. Pricing Analysis

Chapter 4. Zilbrysq (Zilucoplan) Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Generalized Myasthenia Gravis (gMG)
    • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Zilbrysq (Zilucoplan) Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Specialty Pharmacies
    • 5.4.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Hospital/Institution-Based Pharmacies
    • 5.5.1. Hospital/Institution-Based Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Home Healthcare Providers
    • 5.6.1. Home Healthcare Providers Market, 2018 - 2030 (USD Million)

Chapter 6. Zilbrysq (Zilucoplan) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Zilbrysq (Zilucoplan) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. UCB
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives

Chapter 8. Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Zilbrysq (Zilucoplan) Market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 U.S Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 UK Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Germany Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 France Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Italy Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Spain Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Norway Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 China Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Australia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Zilbrysq (Zilucoplan) Market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 UAE Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Zilbrysq (Zilucoplan) Market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Zilbrysq (Zilucoplan) Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Zilbrysq (Zilucoplan) Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication and Distribution Channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Zilbrysq (Zilucoplan) Market dynamics
  • Fig. 12 Zilbrysq (Zilucoplan) Market: Porter's five forces analysis
  • Fig. 13 Zilbrysq (Zilucoplan) Market: PESTLE analysis
  • Fig. 14 Indication market, 2018 - 2030 (USD Million)
  • Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
  • Fig. 16 Others market, 2018 - 2030 (USD Million)
  • Fig. 17 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 18 Specialty Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 19 Hospital/Institution-Based Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 20 Home Healthcare Providers market, 2018 - 2030 (USD Million)
  • Fig. 21 Zilbrysq (Zilucoplan) Market revenue, by region
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 65 MEA Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait Zilbrysq (Zilucoplan) Market, 2018 - 2030 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework